1.710USD-2.29%Mkt Cap: 513.50M USDP/E: —Last update: 2026-05-26
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy wi…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap513.50M USD
Enterprise Value1.42B USD
Revenue (TTM)889.00K USD
Gross Profit889.00K USD
Net Income (TTM)-68.99M USD
Revenue/Share0.0060 USD
Last Price1.710 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.04
PEG—
EV/EBITDA-8.80
EV/Revenue1602.73
P/S594.61
P/B-0.24
EPS (TTM)-0.53
EPS (Forward)-0.58
52W Range
0.540018% of range7.130
52W High7.130 USD
52W Low0.5400 USD
Profitability
Gross Margin100.00%
Oper. Margin-19881.86%
EBITDA Margin0.00%
Profit Margin-7725.20%
ROE6.82%
ROA-20.56%
Growth
Revenue Growth-1.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-120.12M USD
CapEx (TTM)15.20M USD
FCF Margin-8678.95%
FCF Yield-15.03%
Net Debt-221.16M USD
Net Debt/EBITDA1.37
Balance Sheet
Debt/Equity-0.00
Current Ratio9.06
Quick Ratio8.71
Book Value/Sh-7.2110 USD
Cash/Share1.096 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)6.250 USD
Target Range1.000 USD – 12.00 USD
# Analysts6
Ownership
Shares Out.205.20M
Float135.44M
Insiders47.64%
Institutions24.20%
Short Interest
Short Ratio17.8d
Short % Float20.65%
Short % Out.12.86%
Shares Short18.26M
Short (prev mo.)16.68M
Technical
SMA 501.888 (-9.4%)
SMA 2002.306 (-25.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)849.65K
Avg Vol (10d)966.48K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—